The value of progression-free survival to patients with advanced-stage cancer

Nature Reviews Clinical Oncology

Volumn 9, Issue 1, 2012, Pages 41-47

  Fallowfield, Lesley J ^a   Fleissig, Anne ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CISPLATIN; PACLITAXEL; PANITUMUMAB; PEMETREXED; RITUXIMAB; SUNITINIB;

ADVANCED CANCER; ALOPECIA; BRAIN ISCHEMIA; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; COLORECTAL CANCER; CONSERVATIVE TREATMENT; DISEASE ASSOCIATION; DISEASE COURSE; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FOLLICULAR LYMPHOMA; HEADACHE; HUMAN; HYPERTENSION; INFECTION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; METASTASIS; MYALGIA; NEUROPATHY; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; PROFESSIONAL COMPETENCE; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SYSTEMATIC ERROR; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS;

DISEASE PROGRESSION; HUMANS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; SURVIVAL; TREATMENT OUTCOME; UNITED STATES;

EID: 84655160829     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.156     Document Type: Review

References (51)

1. Booth, C. M. & Tannock, I. Reflections on medical oncology: 25 years of clinical trials-where have we come and where are we going? J. Clin. Oncol. 26, 6-8 (2008).
2. Soria, J. C., Massard, C. & Le Chevalier, T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann. Oncol. 21, 2324-2332 (2010).
3. Sargent, D. J. & Hayes, D. F. Assessing the measure of a new drug: is survival the only thing that matters? J. Clin. Oncol. 26, 1922-1923 (2008).
4. Peppercorn, J. M. et al. American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer. J. Clin. Oncol. 29, 755-760 (2011).
5. Burstein, H. J. Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J. Clin. Oncol. 29, 1232-1235 (2011).
6. Ocana, A. & Tannock, I. F. When are "positive" clinical trials in oncology truly positive? J. Natl Cancer Inst. 103, 16-20 (2011).
7. Kirkbride, P. & Tannock, I. F. Trials in palliative treatment-have the goal posts been moved? Lancet Oncol. 9, 186-187 (2008). (Pubitemid 351722934)
8. Hensley, M. L. Big costs for little gain in ovarian cancer. J. Clin. Oncol. 29, 1230-1232 (2011).
9. Fojo, T. & Parkinson, D. R. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin. Cancer Res. 16, 5972-5980 (2010).
10. Fojo, T. & Grady, C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl Cancer Inst. 101, 1044-1048 (2009).
11. Saad, E. D., Katz, A., Hoff, P. M. & Buyse, M. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann. Oncol. 21, 7-12 (2010).
12. Ohorodnyk, P., Eisenhauer, E. A. & Booth, C. M. Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point? Eur. J. Cancer 45, 2249-2252 (2009).
13. Burris, H. 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413 (1997).
14. Hudes, G. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007). (Pubitemid 46849157)
15. Verma, S. et al. In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist 16, 25-35 (2011).
16. Bergmann, L., Hirschfeld, S., Morris, C., Palmeri, S. & Stone, A. Progression-free survival as an end-point in clinical trials of biotherapeutic agents. Eur. J. Cancer Suppl. 5, 23-28 (2007). (Pubitemid 350186299)
17. Dancey, J. E. et al. Recommendations for the assessment of progression in randomised cancer treatment trials. Eur. J. Cancer 45, 281-289 (2009).
18. Panageas, K. S., Ben-Porat, L., Dickler, M. N., Chapman, P. B. & Schrag, D. When you look matters: the effect of assessment schedule on progression-free survival. J. Natl Cancer Inst. 99, 428-432 (2007). (Pubitemid 47073565)
19. Chakravarty, A. & Sridhara, R. Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues. Stat. Methods Med. Res. 17, 515-518 (2008).
20. Oxnard, G. R. et al. Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J. Clin. Oncol. 29, 3114-3119 (2011).
21. Buyse, M. et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J. Clin. Oncol. 25, 5218-5224 (2007). (Pubitemid 350232253)
22. Hurvitz, S. A. Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint. Cancer Treat. Rev. 37, 495-504 (2011).
23. Bast, R. C. et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecol. Oncol. 107, 173-176 (2007). (Pubitemid 47575741)
24. Siena, S. et al. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br. J. Cancer 97, 1469-1474 (2007). (Pubitemid 350175845)
25. Odom, D. et al. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. Int. J. Colorectal Dis. 26, 173-181 (2011).
26. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007). (Pubitemid 46089672)
27. Miller, K. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007).
28. Jones, A. & Ellis, P. Potential withdrawal of bevacizumab for the treatment of breast cancer. BMJ 343, d4946 (2011).
29. Salles, G. et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377, 42-51 (2011).
30. Markman, M. et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol. 21, 2460-2465 (2003). (Pubitemid 46606325)
31. Ozols, R. F. Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. J. Clin. Oncol. 21, 2451-2453 (2003). (Pubitemid 46894005)
32. Stinchcombe, T. E. & West, H. L. Maintenance therapy in non-small-cell lung cancer. Lancet 374, 1398-1400 (2009).
33. Ciuleanu, T. et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374, 1432-1440 (2009).
34. Fallowfield, L. Quality of life: a new perspective for cancer patients. Nat. Rev. Cancer 2, 873-879 (2002). (Pubitemid 37328905)
35. Basch, E. Patient-reported outcomes in drug safety evaluation. Ann. Oncol. 20, 1905-1906 (2009).
36. Patil, S. et al. TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-{alpha}) abstract. J. Clin. Oncol. 28 (Suppl.), a4594 (2010).
37. Joly, F., Vardy, J., Pintilie, M. & Tannock, I. F. Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann. Oncol. 18, 1935-1942 (2007). (Pubitemid 350286228)
38. Osoba, D. Health-related quality of life and cancer clinical trials. Ther. Adv. Med. Oncol. 3, 57-71 (2011).
39. Wenzel, L. B., Huang, H. Q., Armstrong, D. K., Walker, J. L. & Cella, D. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25, 437-443 (2007). (Pubitemid 350002993)
40. Saltz, L. B. Progress in cancer care: the hope, the hype, and the gap between reality and perception. J. Clin. Oncol. 26, 5020-5021 (2008).
41. Olsen E. M., Lin, N. U., Krop, I. E. & Winer, E. P. The ethical use of mandatory research biopsies. Nat. Rev. Clin. Oncol. 8, 620-625 (2011).
42. Catt, S., Langridge, C., Fallowfield, L., Talbot, D. C. & Jenkins, V. Reasons given by patients for participating, or not, in phase 1 cancer trials. Eur. J. Cancer 47, 1490-1497 (2011).
43. Sheik-Yousouf, A., Gandhi, S., Dukhovny, S. & Verma, S. A comparison of physician and patient perceptions of clinically important endpoints in the treatment of metastatic breast cancer (MBC) abstract 63. Eur. J. Cancer Suppl. 8, 77 (2010).
44. Jenkins, V. A., Solis Trapala, I., Parlour, L., Langridge, C. I. & Fallowfield, L. J. The views of patients and the general public about expensive anti-cancer drugs in the NHS: a questionnaire based study. J. R. Soc. Med. Sh. Rep. 2, 69 (2011).
45. Matsuyama, R., Reddy, S. & Smith, T. J. Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J. Clin. Oncol. 24, 3490-3496 (2006). (Pubitemid 46638908)
46. Meropol, N. J. et al. Cancer patient preferences for quality and length of life. Cancer 113, 3459-3466 (2008).
47. Mack, J. W., Weeks, J. C., Wright, A. A., Block, S. D. & Prigerson, H. G. End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J. Clin. Oncol. 28, 1203-1208 (2010).
48. Koedoot, C. G. et al. The content and amount of information given by medical oncologists when telling patients with advanced cancer what their treatment options are. Palliative chemotherapy and watchful-waiting. Eur. J. Cancer 40, 225-235 (2004). (Pubitemid 38077025)
49. Jenkins, V. et al. What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions. J. Clin. Oncol. 29, 61-68 (2011).
50. Fallowfield, L. et al. Discussing expensive anti-cancer drugs. Br. J. Healthcare Management 17, 206-212 (2011).
51. Velikova, G. Use of electronic quality of life applications in cancer research and clinical practice. Expert Rev. Pharmacoecon. Outcomes Res. 4, 403-411 (2004). (Pubitemid 39161966)